person · Reporting owner
Kelsey Stephen Michael
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jiya Acquisition Corp.JYAC · Entity 123583 | Director | November 18, 2020 | November 19, 2020 |
| Revolution Medicines, Inc.RVMD · Entity 606 | See Remarks | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jiya Acquisition Corp.
Report date November 18, 2020 · Filed November 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-11-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date. F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date.
F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination.
Revolution Medicines, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 291,791 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 85 · Balance 291,791 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 286,307 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 5,484 · Balance 286,307 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 65,613 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 65,613 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 22:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,484 | $199.30 | $1,092,978.75 |
DisclosureSEC source: 0001462808-26-000010 · ownership.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 286,307 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3 · balance_after: Includes 65,613 restricted stock units. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 85 | $195.01 | $16,575.63 |
DisclosureSEC source: 0001462808-26-000010 · ownership.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,791 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,031 | $40.74 Strike: $40.74 | $1,630,862.94 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · derivative · entry 12 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,069 Underlying: Common Stock · 128,100 shares Expires 2035-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F12 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 52,500 | $42.45 Strike: $42.45 | $2,228,625.00 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · derivative · entry 11 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,500 shares Expires 2031-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,270 | $205.81 | $672,990.53 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 10 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,876 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F9 · price: The transaction was executed in multiple trades at prices ranging from $205.57 to $206.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F10 · balance_after: Includes 76,251 restricted stock units. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,995 | $204.84 | $1,023,189.29 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 9 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 295,146 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F8 · price: The transaction was executed in multiple trades at prices ranging from $204.46 to $205.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 17,949 | $203.87 | $3,659,309.30 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 8 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,141 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F7 · price: The transaction was executed in multiple trades at prices ranging from $203.45 to $204.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 18,869 | $203.06 | $3,831,550.46 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 7 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 318,090 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F6 · price: The transaction was executed in multiple trades at prices ranging from $202.41 to $203.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 21,447 | $201.75 | $4,326,947.26 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,959 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F5 · price: The transaction was executed in multiple trades at prices ranging from $201.39 to $202.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 13,368 | $200.78 | $2,683,985.60 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 358,406 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F4 · price: The transaction was executed in multiple trades at prices ranging from $200.36 to $201.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 11,833 | $200.11 | $2,367,954.88 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371,774 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F3 · price: The transaction was executed in multiple trades at prices ranging from $199.36 to $200.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 800 | $198.55 | $158,840.16 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 383,607 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. F2 · price: The transaction was executed in multiple trades at prices ranging from $198.35 to $198.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 40,031 | $40.74 | $1,630,862.94 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 22:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 52,500 | $42.45 | $2,228,625.00 |
DisclosureSEC source: 0001462808-26-000007 · ownership.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 344,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,175 | $156.12 | $651,797.66 |
DisclosureSEC source: 0001610717-26-000243 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,876 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 76,251 RSUs. F4 · balance_after: Includes 653 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:57 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,302 | $99.48 | $427,964.68 |
DisclosureSEC source: 0001610717-26-000131 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 295,398 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 84,250 RSUs. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:09 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 47,600 | $0.00 Strike: $102.02 | $0.00 |
DisclosureSEC source: 0001610717-26-000083 · form4.xml · derivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,600 Underlying: Common Stock · 47,600 shares Expires 2036-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:09 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 21,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000083 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,700 F1 · balance_after: Includes 94,676 restricted stock units. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,447 | $76.82 | $418,423.29 |
DisclosureSEC source: 0001610717-25-000422 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,600 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 73,576 restricted stock units. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 21:09 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001610717-25-000361 · form4.xml · derivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,055 Underlying: Common Stock · 25,000 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 21:09 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 25,000 | $48.54 | $1,213,540.00 |
DisclosureSEC source: 0001610717-25-000361 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,047 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F3 · price: The transaction was executed in multiple trades in prices ranging from $48.03 to $48.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 84,000 restricted stock units. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 21:09 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 25,000 | $4.73 | $118,250.00 |
DisclosureSEC source: 0001610717-25-000361 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F2 · balance_after: Includes 84,000 restricted stock units. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 20:38 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,367 | $45.82 | $245,942.24 |
DisclosureSEC source: 0001610717-25-000350 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,047 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 84,000 restricted stock units. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 00:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001610717-25-000339 · form4.xml · derivative · entry 8 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,055 Underlying: Common Stock · 25,000 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 00:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,318 | $46.93 | $61,854.00 |
DisclosureSEC source: 0001610717-25-000339 · form4.xml · nonDerivative · entry 6 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,414 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F6 · price: The transaction was executed in multiple trades in prices ranging from $46.5450 to $47.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 94,426 restricted stock units. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 00:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 23,682 | $45.92 | $1,087,418.24 |
DisclosureSEC source: 0001610717-25-000339 · form4.xml · nonDerivative · entry 5 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 290,732 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F5 · price: The transaction was executed in multiple trades in prices ranging from $45.4650 to $46.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 94,426 restricted stock units. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 00:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 25,000 | $4.73 | $118,250.00 |
DisclosureSEC source: 0001610717-25-000339 · form4.xml · nonDerivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F2 · balance_after: Includes 94,426 restricted stock units. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 00:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001610717-25-000339 · form4.xml · derivative · entry 7 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,055 Underlying: Common Stock · 100,000 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 00:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 55,941 | $44.48 | $2,488,518.60 |
DisclosureSEC source: 0001610717-25-000339 · form4.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,414 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F4 · price: The transaction was executed in multiple trades in prices ranging from $44.12 to $44.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 94,426 restricted stock units. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 00:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 44,059 | $43.58 | $1,919,963.45 |
DisclosureSEC source: 0001610717-25-000339 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,355 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F3 · price: The transaction was executed in multiple trades in prices ranging from $43.12 to $44.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 94,426 restricted stock units. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 00:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 100,000 | $4.73 | $473,000.00 |
DisclosureSEC source: 0001610717-25-000339 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F2 · balance_after: Includes 94,426 restricted stock units. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,289 | $39.83 | $170,830.87 |
DisclosureSEC source: 0001610717-25-000238 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,414 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. F4 · balance_after: Includes 94,426 RSUs. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:40 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,294 | $39.04 | $128,598.75 |
DisclosureSEC source: 0001610717-25-000077 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,051 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 104,850 RSUs. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 128,100 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-25-000054 · form4.xml · derivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,100 Underlying: Common Stock · 128,100 shares Expires 2035-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 36,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000054 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,345 F1 · balance_after: Includes 113,926 restricted stock units. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,663 | $45.40 | $211,717.92 |
DisclosureSEC source: 0001610717-24-000545 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,745 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 77,326 RSUs. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000522 · form4.xml · derivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 16,666 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,888 | $59.45 | $171,694.20 |
DisclosureSEC source: 0001610717-24-000522 · form4.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,408 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F4 · price: The transaction was executed in multiple trades in prices ranging from $59.13 to $59.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 86,400 restricted stock units. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 13,778 | $58.49 | $805,814.60 |
DisclosureSEC source: 0001610717-24-000522 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,296 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F3 · price: The transaction was executed in multiple trades in prices ranging from $58.13 to $59.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 86,400 restricted stock units. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 16,666 | $4.09 | $68,163.94 |
DisclosureSEC source: 0001610717-24-000522 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F2 · balance_after: Includes 86,400 restricted stock units. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000510 · form4.xml · derivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,332 Underlying: Common Stock · 16,666 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,610 | $50.08 | $130,702.28 |
DisclosureSEC source: 0001610717-24-000510 · form4.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,408 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F4 · price: The transaction was executed in multiple trades in prices ranging from $49.95 to $50.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 86,400 restricted stock units. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 14,056 | $49.38 | $694,102.15 |
DisclosureSEC source: 0001610717-24-000510 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,018 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F3 · price: The transaction was executed in multiple trades in prices ranging from $48.95 to $49.94, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 86,400 restricted stock units. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 16,666 | $4.09 | $68,163.94 |
DisclosureSEC source: 0001610717-24-000510 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F2 · balance_after: Includes 86,400 restricted stock units. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,665 | $44.19 | $206,124.42 |
DisclosureSEC source: 0001610717-24-000486 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,408 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 86,400 restricted stock units. Read SEC document |
| September 13, 2024 Filed Sep 16, 2024 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000477 · form4.xml · derivative · entry 4 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,998 Underlying: Common Stock · 16,667 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Read SEC document |
| September 13, 2024 Filed Sep 16, 2024 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 10,701 | $43.65 | $467,045.15 |
DisclosureSEC source: 0001610717-24-000477 · form4.xml · nonDerivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,073 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F4 · price: The transaction was executed in multiple trades in prices ranging from $43.22 to $43.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| September 13, 2024 Filed Sep 16, 2024 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,966 | $42.75 | $255,042.32 |
DisclosureSEC source: 0001610717-24-000477 · form4.xml · nonDerivative · entry 2 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 279,774 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F3 · price: The transaction was executed in multiple trades in prices ranging from $42.19 to $43.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| September 13, 2024 Filed Sep 16, 2024 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 16,667 | $4.09 | $68,168.03 |
DisclosureSEC source: 0001610717-24-000477 · form4.xml · nonDerivative · entry 1 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. F2 · balance_after: Includes 95,476 restricted stock units. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:48 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000427 · form4.xml · derivative · entry 3 Kelsey Stephen Michael · CIK 0001462808 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,665 Underlying: Common Stock · 16,667 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.